Theriva Biologics Aligns with FDA on Phase 3 Trial for Pancreatic Cancer Drug
Event summary
- Theriva Biologics aligned with the FDA on the Phase 3 trial design for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC).
- Additional data from the VIRAGE Phase 2b trial presented at AACR suggests an immune-mediated mechanism of action for VCN-01.
- VCN-01 was administered to retinoblastoma patients under a compassionate use program, expected to provide dosing feasibility and tolerability data.
- Cash and cash equivalents totaled $14.4 million as of March 31, 2026, with a runway into Q1 2027.
The big picture
Theriva Biologics' alignment with the FDA on the Phase 3 trial design for VCN-01 marks a significant step forward in the development of a potential treatment for metastatic pancreatic cancer. The company's focus on immune-mediated mechanisms and repeated dosing regimens reflects broader industry trends towards personalized and targeted cancer therapies. With a cash runway extending into Q1 2027, Theriva Biologics will need to carefully manage its financial resources while advancing its clinical programs.
What we're watching
- Regulatory Progress
- How the FDA's alignment on the Phase 3 trial design will impact the timeline and success of VCN-01's development.
- Clinical Data
- Whether the immune-mediated mechanism of action observed in the VIRAGE trial will translate into durable responses and longer survival in the Phase 3 trial.
- Financial Sustainability
- The pace at which Theriva Biologics can secure additional funding to support its clinical trials and operational expenses.
Related topics